Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2013

View Archived Issues

Astellas Pharma offers overview of second quarter of fiscal 2013

AstraZeneca reviews key events of third quarter 2013

KSR2 mutations associated with obesity and impaired glucose control in humans

New conjugates of mutated rFGF-1 and metal nanoparticles disclosed by Polish group

Alfact Innovation presents phase II results for ALF-5755 in AIH/HBV-related liver disease

STAT3 inhibitor SH-4-54 active against breast cancer, multiple myeloma and brain cancer

Sanofi presents preclinical results for SAR-502250

Bispecific TNF/IL-17A inhibitor engineered for rheumatoid arthritis

Clinuvel Pharmaceuticals reports data from U.S. phase III study of Scenesse

Zalicus to discontinue Z-160 development following phase II results

DengueCide receives EMA orphan drug designation

Omeros reports data from phase I trial of OMS-721

Keryx Biopharmaceuticals provides update from safety extension study of Zerenex

ImmunoGen confirms fifth new ADC license agreement this year

AbbVie prepares new BRD4 inhibitors

SIRT1 activation as a putative strategy for the treatment of Huntington's disease

Revalesio begins phase IIa study of RNS-60 in multiple sclerosis

Allied Healthcare confirms first sale of CardioCel in Europe

Shield Therapeutics files IND for pivotal study of ST-10

Ohr Pharmaceutical patents novel PTP-1B inhibitors

Researchers report novel replication-competent vesicular stomatitis viruses for cancer

Mirrx Therapeutics and Centenary Institute enter agreement

Helsinn grants Chugai commercialization rights for anamorelin in select European markets

Chinese researchers patent novel antitumor drugs

Kyowa Hakko Kirin discontinues phase II studies of bardoxolone methyl

DSMB recommends continuation of phase IIb study of Graspa in AML

GSK reports topline results from phase III study of darapladib in chronic coronary heart disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...